

Profit / (Loss) from Ordinary Activities after Finance Costs but before exceptional items (5 - 6)	1,055.94	1,427.61	1,350.48	5,134.02
Exceptional items	-	-	-	-
Profit / Loss from ordinary activities before Tax (7 - 8)	1,055.94	1,427.61	1,350.48	5,134.02
Tax Expenses	211.19	350.99	270.20	1,092.57
Net Profit / Loss from ordinary activities after Tax (9 - 10)	844.75	1,076.61	1,080.28	4,041.46
Extraordinary Items (net of tax expenses Rs.....Lacs)	-	-	-	-
Net Profit / Loss for period (11 - 12)	844.75	1,076.61	1,080.28	4,041.46
Share of Profit / (Loss) of associates	-	-	-	-
Minority Interest	-	-	-	-
Net Profit / Loss after taxes, Minority Interest and share of Profit / (Loss) of Associates (13 - 14 - 15)	844.75	1,076.61	1,080.28	4,041.46
Paid up Equity Share Capital (Face value of the Share shall be indicated)	1393.39	1393.39	1,016.40	1,393.39
Reserve excluding Revaluation Reserves as per Balance Sheet of Previous Accounting Year	-	-	-	-
Earnings per Share (before Extraordinary Items) (of Rs.10/- each) (not annualised)	-	-	-	-
(a) Basic	6.06	7.73	10.63	29.00
(b) Diluted	5.26	6.70	8.93	25.16

The above Standalone Unaudited Financial Results for the Quarter ended June 30th June, 2012 have been reviewed by Audit Committee and taken on record by board of Directors at their meeting held on August 13, 2012.

The Company opted to publish only Consolidated Financial Results. Standalone results of the Company will be available on Company's website www.vivimedlabs.com and also on BSE & NSE websites.

As per Accounting Standard 17 on Segment Reporting (AS-17), results of the two Segments "Specialty Chemicals" and "Pharma" are reported.

Corresponding numbers of previous period/year have been revised, regrouped, wherever necessary.

For VIVIMED LABS LIMITED

(SANTOSH VARALWAR)
MANAGING DIRECTOR & CEO

Place: Hyderabad

Date: 13/08/2012